National Institutes of Health logo
NIH Phase 1 Exploratory/Developmental Cooperative Agreement (UG3)

NIAMS Clinical Trial Implementation Cooperative Agreement (UG3/UH3)

Funds the implementation of a clinical trial in arthritis, musculoskeletal or skin disease as a phased cooperative agreement with the institute.

OpenNational Institutes of HealthUnited States

This is the National Institute of Arthritis and Musculoskeletal and Skin Diseases' route for actually running a trial, once there is one to run.

The mechanism is a phased cooperative agreement. Phased means the second stage depends on the first meeting its milestones. Cooperative means institute staff take an active part in the project rather than watching it.

The scope is the institute's own mi…

Phased cooperative agreements implementing clinical trials within the mission of the National Institute of Arthritis and Musculoskeletal and Skin Diseases, covering arthritis and rheumatic diseases, musculoskeletal conditions and skin diseases. A clinical trial is required.

CycleiHow often this grant runs — e.g. annually, on a rolling basis, or a one-off call.Multiple per year
Next deadlineiThe next date applications are due. Rolling means you can apply any time.4 Mar 2027
Decision timeiTypical time from the deadline to the funder's decision.26 weeks
Project durationiHow long the funded work is expected to run.—
Award typeiThe form of funding — grant, equity, loan, tax credit, etc.Cooperative agreement
Match fundingiThe share of project costs you must cover yourself. 0% = fully funded.—
Funding pooliThe total budget available across all awards in this round.—

Sign up free to see the funding breakdown

Sign up free to see the industries in scope

Sign up free to see the full eligibility

Sign up free to see how to apply

Sign up free to see what you submit

Sign up free to see how they score you

Sign up free to see the timeline

Sign up free to see where teams trip up

Last verified: 25 Aug 2026Funder reference: PAR-25-141Source: www.grants.gov